相关实验视频

Updated: Feb 22, 2026

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

积极降低胆固醇在Jak2V617F小鼠中使动脉样硬化回归正常化

Brian D Hardaway¹, Trevor P Fidler², Mojdeh Tavallaie¹

¹Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Journal of lipid research

|February 20, 2026

概括

通过减少炎症酶激活和促进斑块稳定,积极的降低LDL阻止了Jak2^VF MPN小鼠的动脉样硬化进展. 这表明,密集的胆固醇管理可能会逆转JAK2^VF CHIP或MPN的个体的心血管疾病风险.

科学领域:

心血管生物学心血管生物学
血液学血液学血液学
免疫学免疫学免疫学

背景情况:

这种JAK2^V617F (JAK2^VF) 突变驱动着克隆性血液形成和骨髓增殖性瘤 (MPN).
JAK2^VFCHIP和MPN模型表现出由于巨细胞炎症酶激活的加速动脉样硬化.
据推测,持续的炎症会阻碍JAK2^VF小鼠的动脉样硬化解决.

研究的目的:

评估正在进行的炎症是否会阻碍JAK2^VF小鼠的动脉样硬化解决.
为了研究LDL胆固醇降低对JAK2^VF MPN模型中的动脉样硬化的影响.
阐明降低LDL影响斑块炎症和稳定的机制.

主要方法:

化学JAK2^VF/WT或WT/WT骨髓移植到Ldlr^-/-小鼠中.
西方饮食引起的动脉样硬化,其次是中度或明显的LDL胆固醇降低.
病变进展,巨细胞负担,原蛋白含量和炎症和巨细胞激活的分子标记物的分析.

主要成果:

与对照组相比,中度的LDL降低了JAK2^VF MPN小鼠中的损伤分辨率.
显著的LDL降低在JAK2^VF MPN和对照小鼠中停止了病变的进展.
降低LDL可以逆转JAK2^VF巨细胞炎症酶激活,并增加TREM2和c-Myc的表达.

结论:

积极的LDL降低逆转了炎症酶激活,并促进了JAK2^VF MPN中的亲溶解性巨细胞变化.
强化降低LDL胆固醇可以阻止动脉样硬化进展,并稳定JAK2^VF MPN中的斑块.
积极的LDL降低可能会逆转JAK2^VF CHIP或MPN患者的动脉样硬化心血管疾病风险.

关键词:

杰克2 (((V617F) 突变的发生.这就是为什么LDL,LDL是LDL.在黑色素瘤2中不存在.动脉样硬化斑块回归回归骨髓骨髓骨髓骨髓骨髓克隆性血液形成 (clonal hematopoiesis) 是一种细胞形成的过程.泡细胞是一种泡细胞.一些炎症一些炎症这是一种炎症炎症炎症炎症.血管生物学血管生物学

更多相关视频

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...